Kodiak Sciences (KOD) Races Toward Three Make-Or-Break Trial Verdicts

Kodiak Sciences Inc. (KOD) is on the verge of three critical Phase 3 trial verdicts, which will significantly impact its future. The biotech firm reported a widening cash burn and a $65.6 million net loss in Q2 2026, despite promising data from its two lead candidates, Zenkuda and KSI-101. Zenkuda, already tested in four Phase 3 studies, is set to deliver one-year topline data for wet age-related macular degeneration in September 2026, while KSI-101 in PEAK is evaluating its efficacy in macular edema secondary to inflammation.

Kodiak also began enrolling patients in ALTO, a trial testing KSI-501 against aflibercept in diabetic macular edema. These trials will determine whether the company's novel treatments can compete in a $15 billion anti-VEGF market. With three trials due between September and December, any disappointing results could severely impact Kodiak's already thinning equity cushion.